Alignment Healthcare Inc

ALHC remains in a Stage 2 corrective advance but has stalled under its short EMAs, making current timing unfavorable for bullish engagement. The medium-term bias stays bullish, supported by higher lows and a rising 50-DMA, but price action under 9/21 EMAs warrants a deferred entry. Execution should stalk pullbacks into the rising 50-DMA and base support for potential acceptance. A decisive reclaim above the short EMAs with follow-through would validate the bullish posture, while a drop below the 50-DMA would invalidate.

• ↑Membership grew 31% YoY to 284.8K; Q1 2026 revenue rose 33% to $1.2B.
• ↑Q1 adjusted EBITDA reached $38M (3.1% margin), up 88% YoY; cash $726M.
• ↓Securities fraud probe and whistleblower suit triggered a 16.7% share price drop.